First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival ...
Approximately one-third of patients with relapsed or refractory mantle cell lymphoma (MCL) in this study treated with CAR T-cell therapy experienced disease progression, with a median progression time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback